Capital Markets

Cooley advised Uber on its $8.1 billion initial public offering of 207,000,000 shares of common stock. Uber, whose securities now trade on the NYSE under the symbol “UBER,” is a mobility platform revolutionizing the personal ridesharing, meal delivery and logistics industries. Partners Dave Peinsipp, Siana Lowrey, Drew Williamson, Charlie Kim and Kristin VanderPas led the Cooley team.

Cooley advised Zoom on its $864 million initial public offering of 24,000,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Zoom, whose securities now trade on the Nasdaq Global Select Market under the symbol “ZM,” helps businesses and organizations bring their teams together in a frictionless environment to get more done. The company’s easy, reliable cloud platform for video, voice, content sharing and chat runs across mobile devices, desktops, telephones and room systems. Partners Jon Avina, Calise Cheng and Bradley Libuit led the Cooley team.

Cooley advised Snowflake on its $3.9 billion initial public offering of 32,200,000 Class A shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Snowflake, whose securities now trade on the New York Stock Exchange under the symbol “SNOW,” is a cloud software company pioneering the data cloud, an ecosystem where customers, partners and data providers can break down data silos and derive value from rapidly growing data sets in secure, governed and compliant ways. Partners Mark Tanoury, Jon Avina and Seth Gottlieb led the Cooley team.

Cooley advised Instacart, the leading grocery technology company in North America, on its $660 million initial public offering.

Cooley advised Legend Biotech on its $487.3 million initial public offering of 21,188,750 American Depository Shares (ADSs). Legend Biotech, whose securities now trade on the Nasdaq Global Select Market under the symbol “LEGN”, is global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Partners Div Gupta, Rob Phillips, Will Cai, Michael Yu and Rich Segal led the Cooley team.